| Intensive versus moderate lipid lowering with statins after acute coronary syndromes cannon cp | 6590* | 2004 |
| Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia DL Bhatt, PG Steg, M Miller, EA Brinton, TA Jacobson, SB Ketchum, ... New England Journal of Medicine 380 (1), 11-22, 2019 | 2875 | 2019 |
| Triglycerides and cardiovascular disease: a scientific statement from the American Heart Association M Miller, NJ Stone, C Ballantyne, V Bittner, MH Criqui, HN Ginsberg, ... Circulation 123 (20), 2292-2333, 2011 | 2320 | 2011 |
| Dietary fats and cardiovascular disease: a presidential advisory from the American Heart Association FM Sacks, AH Lichtenstein, JHY Wu, LJ Appel, MA Creager, ... Circulation 136 (3), e1-e23, 2017 | 1461 | 2017 |
| Effect of amlodipine on the progression of atherosclerosis and the occurrence of clinical events B Pitt, RP Byington, CD Furberg, DB Hunninghake, GBJ Mancini, ... Circulation 102 (13), 1503-1510, 2000 | 1257 | 2000 |
| Omega-3 fatty acids and coronary heart disease risk: clinical and mechanistic perspectives WS Harris, M Miller, AP Tighe, MH Davidson, EJ Schaefer Atherosclerosis 197 (1), 12-24, 2008 | 865 | 2008 |
| A null mutation in human APOC3 confers a favorable plasma lipid profile and apparent cardioprotection TI Pollin, CM Damcott, H Shen, SH Ott, J Shelton, RB Horenstein, W Post, ... Science 322 (5908), 1702-1705, 2008 | 847 | 2008 |
| Extended-release niacin or ezetimibe and carotid intima–media thickness AJ Taylor, TC Villines, EJ Stanek, PJ Devine, L Griffen, M Miller, ... New England Journal of Medicine 361 (22), 2113-2122, 2009 | 830 | 2009 |
| Impact of triglyceride levels beyond low-density lipoprotein cholesterol after acute coronary syndrome in the PROVE IT-TIMI 22 trial M Miller, CP Cannon, SA Murphy, J Qin, KK Ray, E Braunwald, ... Journal of the American College of Cardiology 51 (7), 724-730, 2008 | 821 | 2008 |
| Association between C reactive protein and coronary heart disease: mendelian randomisation analysis based on individual participant data C Reactive Protein Coronary Heart Disease Genetics Collaboration Bmj 342, 2011 | 669 | 2011 |
| Cardiovascular efficacy and safety of bococizumab in high-risk patients PM Ridker, J Revkin, P Amarenco, R Brunell, M Curto, F Civeira, ... New England Journal of Medicine 376 (16), 1527-1539, 2017 | 655 | 2017 |
| Statin safety and associated adverse events: a scientific statement from the American Heart Association CB Newman, D Preiss, JA Tobert, TA Jacobson, RL Page, LB Goldstein, ... Arteriosclerosis, thrombosis, and vascular biology 39 (2), e38-e81, 2019 | 590 | 2019 |
| Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial HJL Heerspink, HH Parving, DL Andress, G Bakris, R Correa-Rotter, ... The Lancet 393 (10184), 1937-1947, 2019 | 496 | 2019 |
| Driver fusions and their implications in the development and treatment of human cancers Q Gao, WW Liang, SM Foltz, G Mutharasu, RG Jayasinghe, S Cao, ... Cell reports 23 (1), 227-238. e3, 2018 | 482 | 2018 |
| Comparative molecular analysis of gastrointestinal adenocarcinomas Y Liu, NS Sethi, T Hinoue, BG Schneider, AD Cherniack, F Sanchez-Vega, ... Cancer cell 33 (4), 721-735. e8, 2018 | 480 | 2018 |
| International, randomized, controlled trial of lamifiban (a platelet glycoprotein IIb/IIIa inhibitor), heparin, or both in unstable angina E Topol, R Califf, F Van de Werf, R Diaz, E Paolasso, P Aylward, J Simes, ... Circulation 97 (24), 2386-2395, 1998 | 431 | 1998 |
| Omega-3 fatty acids for the management of hypertriglyceridemia: a science advisory from the American Heart Association AC Skulas-Ray, PWF Wilson, WS Harris, EA Brinton, PM Kris-Etherton, ... Circulation 140 (12), e673-e691, 2019 | 394 | 2019 |
| Characterization of myocardial injury in patients with COVID-19 G Giustino, LB Croft, GG Stefanini, R Bragato, JJ Silbiger, M Vicenzi, ... Journal of the American College of Cardiology 76 (18), 2043-2055, 2020 | 390 | 2020 |
| Somatic mutational landscape of splicing factor genes and their functional consequences across 33 cancer types M Seiler, S Peng, AA Agrawal, J Palacino, T Teng, P Zhu, PG Smith, ... Cell reports 23 (1), 282-296. e4, 2018 | 379 | 2018 |
| Effect of intensive lipid lowering with atorvastatin on renal function in patients with coronary heart disease: the Treating to New Targets (TNT) study J Shepherd, JJP Kastelein, V Bittner, P Deedwania, A Breazna, S Dobson, ... Clinical Journal of the American Society of Nephrology 2 (6), 1131-1139, 2007 | 371 | 2007 |
